Provided are compositions, devices and systems, methods for assessing, treating and/or preventing an intraocular disease or disorder in a subject, wherein the etiology of the intraocular disease or disorder comprises infection of a microorganism in the intraocular space or cavity of the subject. Provided are compositions, devices and systems, and methods for assessing, treating and/or preventing age-related macular degeneration (AMD) in a subject, e.g., a human patient.

Systems and methods for determining the osmolarity of a sample are provided. Aspects of the subject methods include contacting a sensing surface of a surface plasmon resonance based sensor with a sample, and generating one or more data sets at at least two wavelengths over a time interval, wherein the data sets are used to determine the osmolarity of the sample. The subject methods find use in determining the osmolarity of a sample, such as a biological sample (e.g., a tear fluid), and in the diagnosis and/or monitoring of various diseases and disorders, such as, e.g., dry eye disease.

Methods of identifying subjects having complement-related disorders, or at risk of such disorders, are disclosed. Also disclosed are methods for selecting subjects for treatment with complement-targeted therapies, and methods of treatment of subjects with such therapies.

Optical sensors, systems and methods of use thereof are provided. Aspects of the subject systems include a sensor having a sensing surface and a configuration that directs a first optical signal to interact with the sensing surface at a first incident angle, and directs a second optical signal to interact with the sensing surface at a second incident angle. The subject sensors, systems and methods find use, e.g., in the diagnosis of dry eye disease.

The present disclosure provides a marker that shows a relationship with changes in the nerve density and morphology in the cornea. In one aspect, the present invention provides a marker for neuropathy in the eye, the expression of which changes in correlation with morphological parameters of the nerves in the eye. In some embodiments, the parameter may include at least one parameter selected from the group consisting of CNBD, CTBD, CNFD, CNFL, and tortuosity. In a particular embodiment, the parameter may include at least one parameter selected from CNBD and CTBD.

Antibodies comprising an antigen recognition region which binds a semaphorin 3A (Sema3A) are disclosed. Uses thereof are also disclosed.

The present invention is directed to compositions and methods for the treatment of degenerative retinal conditions. According to a general aspect, the present invention is directed to inflammatory mediators, preferably components or substrates of the NLRP3-inflammasome, for use in the treatment of degenerative retinal conditions involving drusen and anaphylatoxin-induced choroidal-neovascularisation. The invention is also directed to a method for the treatment of degenerative retinal conditions involving drusen and anaphylatoxin-induced choroidal-neovascularisation and to recombinant vectors and recombinant proteins for use in such methods. The present invention also provides a method for determining the risk of developing or monitoring the progression of diseases involving drusen and anaphylatoxin-induced choroidal neo-vascularisation.

The present invention relates to biocompatible compositions comprising one or more crystallin proteins, and the use of such compositions in therapeutic and research methods, for example in surgical methods, in sustained release drug delivery, and in cell-based methods.

The present disclosure provides methods of treating subjects having an ophthalmic condition, methods of identifying subjects having an increased risk of developing an ophthalmic condition, and methods of detecting Angiopoietin-Like 7 (ANGPTL7) variant nucleic acid molecules and variant polypeptides.

Provided herein, in one aspect, is a population of retinal neurons including photoreceptors precursor cells (PRPCs) generated in vitro from human pluripotent stem cells (hPSCs) that can be used as a cell source for regenerative therapies, drug discovery and disease modeling. Methods and compositions for making and using the same are also provided.